Overview

Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibitor alone.
Phase:
N/A
Details
Lead Sponsor:
Stanford University
Collaborator:
National Institutes of Health (NIH)
Treatments:
Furosemide